Jun 05, 2023 2023 Global M&A Intelligence Report – Life Sciences Supplement By Victoria Rhodes Robert Newman The DLA Piper Life Sciences sector team is delighted to announce the launch of our new 2023 Global M&A Intelligence Report – Life...
Oct 19, 2022 EU Pharma & Medical Device Regulation 2023 By Marco de Morpurgo Nicola Landolfi Our EU Life Sciences Regulatory team led by Marco de Morpurgo and Nicola Landolfi have produced a guide on EU Pharma & Medical Device...
May 17, 2021 Interactions with healthcare professionals – launch of the new DLA Piper interactive compliance site for pharmaceutical companies By Marco de Morpurgo Andrzej Balicki, Ph.D. Ethical relations with healthcare professionals are of vital importance for pharmaceutical companies. Cooperation with them results in a...
Apr 23, 2020 Clinical trials during the COVID-19 pandemic: A global guide By Dr Kokularajah Paheenthararajah After weeks of intensive collaboration and inspiring contributions from more than 100 Life Sciences enthusiasts across five continents,...
Jul 26, 2023 European Medicines Agency opens dialogue on use of AI in pharmaceutical life cycle By Danny Tobey Keo Shaw Marco de Morpurgo To open a dialogue with developers, academics, and regulators, the European Medicines Agency (EMA) recently published a draft Reflection...
Nov 23, 2020 Telehealth around the world: A global guide By Greg Bodulovic Marco de Morpurgo The COVID-19 pandemic has caused healthcare systems around the globe to rapidly, and in some cases, radically rethink the delivery of...
Jan 25, 2022 Update: DLA Piper Global COVID-19 Vaccine Guide for Employers By Marco de Morpurgo DLA Piper’s Life Sciences team has updated our recent vaccine guide for employers. The changes include significant updates to several...
Oct 05, 2021 Update: DLA Piper Global COVID-19 Vaccine Guide for Employers By Marco de Morpurgo DLA Piper’s Life Sciences team has updated our recent vaccine guide for employers. The changes include the additions of Sweden and...
May 25, 2021 Launch of DLA Piper Global COVID-19 Vaccine Guide for Employers By Pilar Menor Marco de Morpurgo As the scientific response to the COVID-19 pandemic develops, many employers are considering what their approach should be to the issues...
Mar 16, 2021 Wearable technologies: legal lifecycle of taking a new product to market By Marco de Morpurgo Wearable devices is a term used for electronic devices that can be worn on the body, either as an accessory like a watch or a pair of...
May 26, 2023 EU Pharma Law Revision: First Reactions and Next Steps By Marco de Morpurgo Laetitia Mouton Mary Foord-Weston Exactly one month ago, on 26 April 2023, the European Commission (EC) adopted its long-awaited proposal for the revision of the EU...
Apr 03, 2020 European Commission proposes one-year postponement of MDR application date By Mark Franklin Marco de Morpurgo Paula Gonzalez de Castejón Llano-Ponte Nicola Landolfi +1 more... Show less Following an informal heads-up on 25 March 2020, today the European Commission adopted a proposed regulation to postpone by one year the...
Mar 20, 2023 Extended transition period gives medical device industry extra time to comply with EU MDR By Marco de Morpurgo Nicola Landolfi A much-awaited extension of the MDR transition period became effective today with the publication of Regulation (EU) 2023/607 in the...
Feb 06, 2023 Clinical trials in the EU: mandatory CTIS procedures and new transparency requirements from 31 January 2023 By Marco de Morpurgo Nicola Landolfi On 31 January 2023, the new Clinical Trials Information System (CTIS) established by Regulation (EU) 536/2014 on clinical trials (CTR)...
Nov 15, 2022 Clinical Trials and Privacy Matters: A Cross-border Guide By Marco de Morpurgo This week our Life Sciences team published the first edition of its Cross-border Guide to Clinical Trials and Privacy. The Guide will...
Oct 06, 2022 New IFPMA/EFPIA guidance on social media and digital channels By Marco de Morpurgo Carlotta Busani The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the European Federation of Pharmaceutical...